Search clinical trials for: dabigatran (Pradaxa)

Total 302 results

Boehringer Ingelheim

Completed

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

Healthy Volunteers

China
University of Alberta

Completed

Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke (DATAS)

Transient Ischemic Attack | Minor Ischemic Stroke

Canada
Boehringer Ingelheim

Completed

Medical Need of OAC Reversal

Atrial Fibrillation

Japan
University of Utah

Terminated

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation (DEPAF)

Atrial Fibrillation

United States
Centre Hospitalier Universitaire de Saint Etienne
Groupe de Recherche sur la Thrombose

Completed

Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin (IMAGINE)

Healthy

France
Ross Leighton
Nova Scotia Health Authority

Withdrawn

A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days

Thromboembolism

Canada
Irina Ermolaeva

Recruiting

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD (RE-ELECT)

Chronic Kidney Diseases | Atrial Fibrillation | T2DM (Type 2 Diabetes Mellitus)

Russian Federation
Boehringer Ingelheim

Completed

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Atrial Fibrillation

Taiwan
Boehringer Ingelheim

Completed

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

Healthy

Japan
Boehringer Ingelheim

Completed

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Atrial Fibrillation

Korea, Republic of
Vanderbilt University Medical Center
Boehringer Ingelheim

Completed

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

Atrial Fibrillation | Atrial Flutter

United States
Boehringer Ingelheim

Recruiting

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot (DaPaR)

Venous Thromboembolism

Spain, Germany, Netherlands, Czechia, Finland, Sweden
Daiichi Sankyo Co., Ltd.

Completed

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

Healthy Subjects | Pharmacokinetics | Drug-drug Interaction | Quizartinib

United States
The University of Hong Kong

Recruiting

Dabigatran for Mitral Stenosis Atrial Fibrillation

Atrial Fibrillation | Mitral Stenosis

Hong Kong
Bayer

Completed

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Hot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Kyunghee University Medical Center

Unknown

Pleotropic Effect of New Oral Anticoagulants

Atrial Fibrillation

Korea, Republic of
Intermountain Health Care, Inc.
Boehringer Ingelheim

Completed

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF)

Dementia | Cognition Disorders | Cerebral Ischemic Events

United States
Medical University of South Carolina
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Interstitial Lung Disease | Scleroderma

United States
Research Institute for Complex Problems of Cardiovascular...

Unknown

Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses

Atrial Fibrillation | Mitral Valve Stenosis and Insufficiency

Russian Federation
Boehringer Ingelheim

Completed

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Atrial Fibrillation

United States, Canada
Peking University Third Hospital

Recruiting

Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults

Health

China
Corcept Therapeutics

Completed

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Neoplasms | Cushing Syndrome

United States
Nova Scotia Health Authority
Dalhousie University; Université de Montréal; Capital Health, Canada

Completed

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

Blood Coagulation Disorders

Canada
University Hospital, Grenoble

Completed

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics (REVNEWANTICO)

Venous Thromboembolism

France
Johannes Gutenberg University Mainz
Boehringer Ingelheim; Atrial Fibrillation Network

Terminated

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF (RE-LATED_AF)

Atrial Fibrillation or Atrial Flutter | Thrombosis of Left Atrial Appendage

Germany
Mayo Clinic

Terminated

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

Acute Pancreatitis

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Completed

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

Healthy

Belgium
Lawson Health Research Institute
Boehringer Ingelheim

Completed

DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation (DAPPARAF)

Atrial Fibrillation

Canada
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
Wuhan Asia Heart Hospital

Completed

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy (DIRECT)

Atrial Fibrillation | Strokes Thrombotic

China
Boehringer Ingelheim

Completed

Japanese Pradaxa PMS, Long Term

Atrial Fibrillation

Japan
Odense University Hospital

Completed

Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation

Atrial Fibrillation

Denmark
National Cheng-Kung University Hospital
Tainan Municipal Hospital; E-DA Hospital; Ministry of Health and Welfare, Taiwan and other collaborators

Unknown

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation (DARING-AF)

Atrial Fibrillation

Taiwan
Hospital Ana Nery

Terminated

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively (DAWA)

Primary Disease

Brazil
Boehringer Ingelheim
SITS international registry, Karolinska University Hospital, Stockholm, Sweden

Completed

This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke

Atrial Fibrillation

Sweden
University of Alberta
Boehringer Ingelheim

Completed

Canadian Pradaxa Acute Stroke Safety Study (CPASS)

Stroke | Ischemic Attack, Transient

Canada
Prof. Stavros Konstantinides, MD
European Georges Pompidou Hospital

Terminated

Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. (PEITHO-2)

Pulmonary Embolism

Germany
Vanderbilt University Medical Center
Boehringer Ingelheim

Completed

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). (DEA-LAA)

Atrial Fibrillation | Left Atrial Appendage Thrombosis | Device Related Thrombus | Watchman LAA Closure Device

United States
The University of Hong Kong

Unknown

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism

Hong Kong
Boehringer Ingelheim

Completed

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

Atrial Fibrillation

Japan
University of Sao Paulo General Hospital

Completed

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

Hemorrhage | Atrial Fibrillation | Periodontal Disease

Brazil
Deutsches Herzzentrum Muenchen

Completed

Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation (Dabi-ADP-1)

Atrial Fibrillation

Germany
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Myocardial Infarction | Ischemic Stroke | Atrial Fibrillation | All-cause Mortality | Systemic Embolization | Major Bleed

Canada
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Gines Escolar
Ministry of Health, Spain

Unknown

Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)

Hemorrhage | Thrombosis | Anticoagulant-induced Bleeding | Anticoagulant Overdosage

Spain
Fundació Institut de Recerca de l'Hospital de la...
Daiichi Sankyo

Recruiting

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD) (MACACOD)

Atrial Fibrillation | Recurrent Venous Thromboembolism

Spain
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners (PRACTISE)

Venous Thromboembolism (VTE)

Sweden
Hong Kong WD Pharmaceutical Co., Limited

Unknown

A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Anticoagulant
Boehringer Ingelheim

Completed

Patient Convenience Study- NIS RELATE

Atrial Fibrillation

Korea, Republic of, Malaysia, Singapore, Thailand, Indonesia

3

Subscribe